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YULE, D. I. AND J. A. WILLIAMS. CCK antagonists reveal that CCK-8 and JMV- 180 interact with different sites on the rat paturreatic 
acinar cell CCKA receptor. PEPTIDES 15(6) 1045-1051, 1994.--The ability of CCKA antagonists to inhibit full and partial ~ agnnists 
of the rat pancreatic acinar cell CCKA receptor has been studied. When isolated rat pancreatic acini were supcffnsed with CCK-8 (10 
pM-I nM) or CCK-4 (1 gag), an increase in [Ca2+]i signal was initiated. Concurrent superfusion of either L-364,718 (0.1 gait) or 
lorglurnide (10 #At/), chemically distinct, specific, potent antagonists of the CCKA receptor, resulted in a rapid inhibition of the [Ca2+]i 
signal initiated by all concentrations of C~K-8. In contrast, Ca 2+ oscillations, initiated by JMV-180 (25 nM-1 gM), a partial agonist 
analogue of CCK-8, were essentially unaffected by concurrent superfnsion of either L-364,718 or lotglumide. When JMV-179, an 
analogue of JMV-180 that exhibits characteristics of a pure antagonist, was supcffused concurrently with either CCK-8 or JMV-180, 
Ca 2+ oscillations were inhibited, even in the presence of 0.1 ~ L-364,718. In a similar fashion, amylase secretion stimulated by CCK- 
8 was markedly attenuated by L-364,718, lorglumide, and JMV-179, whereas secretion stimulated by JMV-180 was only inhibited by 
JMV-179. A model is proposed to reconcile this data, based on the assumption that JMV-180 and CCK-8 interact with discrete sites 
on the CCKA receptor, which are differentially affected by the binding of antagonists. This model may also explain how a single receptor 
may transduce multiple signals in response to different agonists. 
Cholecystokinin JMV-180  Antagonists [Ca2+]i oscillations Pancreatic acinar cells Amylase secretion 
CHOLECYSTOKININ (CCK) binding to specific receptors on 
the plasma membrane of pancreatic acinar cells results in a cas- 
Cade of intracellular events that ultimately lead to a variety of 
biological responses, including digestive enzyme secretion 
(29,30). Investigation of CCK binding to its receptor has revealed 
that the receptor exists in multiple affinity states (2,10,15,20), 
and by comparison of dose-response relationships for binding 
and resultant physiological events, the occupancy of specific af- 
finity states of the receptor has been related to the observed 
biologica~ responses. CCK-stimulated secretion of digestive en- 
zymes and protein synthesis are attributed to binding to a high- 
affinity state of the receptor, whereas inhibition of secretion and 
protein synthesis, together with the stimulation of glucose trans- 
port, IJy supramaximal concentrations are thought to be me- 
diated by binding to a low-affinity state (13,15,20,29,30). Much 
of the evidence for this concept has been obtained using the 
partial analogue of CCK-8, JMV- 180 (6,7,15,16,23) (Table 1 ), 
which has been reported to act as an agonist at the high-affinity 
state of the CCK^ receptor. Paradoxically, although stimulation 
with JMV-180 results in full secretion, it does not appear to 
activate an identical sequence oftransduction events compared 
to CCK. For example, the binding of CCK-8 to the CCKA re- 
ceptor has been reported to be guanine nucleotide sensitive, 
whereas the binding of CCK-OPE, a similar analogue to JMV- 
180, is not (6). Moreover, JMV-180, in contrast to CCK, appears 
to increase intracellular Ca 2+ by an 1,4,5-IP3 independent route, 
because Ca 2+ signaling stimulated by this molecule is insensitive 
to inhibitors of phospholipase C-coupled events or to inhibitors 
of the IP3 receptor (19,26,31). These studies suggest that JMV- 
180 and CCK, although binding to the same receptor, may ac- 
tivate distinct transduction mechanisms. Although only a little 
is known about binding domains ofpeptide receptors, evidence 
from study of the CCKB receptor has indicated that different 
sites may be responsible for conferring either agonist or antag- 
onist binding properties (1). In this study, we have investigated 
the possibility that JMV-180 and CCK-8 bind to different sites 
on the CCKA receptor by investigating the interaction of antag- 
onists and agonists of the CCKA receptor. 
METHOD 
Chemicals 
Fura-2/AM and fura-2 free acid was purchased from Molec- 
ular Probes (Eugene, OR); lorglumide (also known as CR 1409) 
~Reque~sforrepfin~shouldbeaddressed to David I. Yule, Depa~ment of Physiology, Unive~ity of Michigan, 7737MedScilI, Ann Arbor, 
MI 48109-0622. 
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Primary amino acid sequence of CCK and the analogues utilized during 
this study. The primary functional modification in JMV-180 is at the 
carboxy-terminus. In JMV-179 a D-Trp for L-Trp substitution has been 
made. Boc = t-butyloxycarbonyl; Ahx = 6 aminohexanoic acid (nodeu- 
cine). 
was from RBI (Natick, MA); JMV- 180 and JMV- 179 were from 
Research Plus (Bayonne, NJ); collagenase was from Worthington 
Biochemicals (Freehold, N J); bovine serum albumin (fraction 
V) was from ICN Imunobiologicals (Lisle, IL); minimal essential 
amino acids were from GIBCO (Grand Island, NY); L-364,718 
(also known as MK-329 or devazepide) was a gift from Merck 
Sharp and Dohme (West Point, PA). CCK-8 was a gift from 
Squibb Research Institute (Princeton, N J). All other chemicals 
were obtained from Sigma Chemical (St. Louis, MO). 
Preparation of  Pancreatic Acini 
Acini were prepared by methods as previously described 
(16,28,31). In brief, pancreata were excised from fed adult male 
Sprague-Dawley rats (200-250 g) and acini were prepared by 
enzymatic digestion with purified collagenase. Acini were then 
suspended in a physiological salt solution (PSS) containing an 
essential amino acid mixture, 10 mg/ml BSA, 0.1 mg/ml soybean 
trypsin inhibitor (SBTI), and (in raM): 137 NaC1, 4.7 KCI, 0.56 
MgClz, 1.28 CaCI2, 1.0 Na2HPO4, 10 HEPES, 2 L-glutamine, 
5.5 D-glucose. The pH was adjusted to 7.4 and equilibrated with 
100% 02. 
Measurement o f  lntracellular [ Ca2+ ]i 
Isolated acini were incubated with 1 #M fura-2/AM at am- 
bient temperature for 30 rain and then washed and resuspended 
in fresh PSS. For measurement of  intracellular [Ca2+], fura-2- 
loaded acini were transferred to a closed 100-#1 chamber, 
mounted on the stage of a Zeiss Axiovert inverted microscope, 
and continuously superfused at 1 ml/min with PSS at 37°C. 
Solution changes were rapidly accomplished by means of a valve 
attached to an eight-chambered superfusion reservoir. Mea- 
surement of intracellular [Ca 2+] was performed using an Atto- 
fluor digital imaging system (RockviUe, MD). In brief, excitation 
of cells at 334 and 380 (10 nm bandpass) was accomplished by 
a computer-selectable filter and shutter system. Resultant emis- 
sion at 510 nm was monitored by an intensified CCD camera 
and subsequently digitized. Calibration of [Ca2+]i signals was 
determined by applying the equation of Grynkiewicz (9). The 
fluorescent emission of external Ca 2+ standards containing 1 
#M fura-2 either in the absence (1 m M  EGTA) or presence of 
Ca 2+ (1 raM) was monitored allowing the determination of R ~ ,  
Rmin and 8. The calibration was then applied to user-defined 
areas of interest, where mean gray level values were computed 
to give a measurement of [Ca2+]i as described previously 
(3,32,33). 
Measurement of Amylase Release 
Acini were incubated for 30 min in the presence of the in- 
dicated agents. In samples incubated with both antagonists and 
agonists, the antagonists were added 30 s prior to addition of 
agonists. After stimulation of acini, samples were centrifuged 
for 10 s in an Eppendorf microcentrifuge. Amylase was deter- 
mined in the supernatant using procion yellow starch as substrate 
(12). At the beginning of the incubation period, a 1-ml aliquot 
of acinar suspension was centrifuged and amylase determined 
in the supernatant. This zero time value was subtracted from 
the values obtained after incubation. The pellets were resus- 
pended in water and sonicated to determine total acinar amylase 
content. Amylase release during incubation was expressed as 
percentage of the total amylase content at the beginning of the 
incubation. 
RESULTS 
L-364, 718 Inhibits Ca 2+ Oscillations Induced by CCK But Not 
JMV-180 
On stimulation with low concentrations of CCK-8 or JMV- 
180 the intracellular [Ca2+]i signal showed a characteristic os- 
cillatory increase. The [Ca2+]i signal rose from basal values of 
96 -+ 3 riM(28 expt, 325 cells) and peaked at 313 +_ 27 nMfor  
20 pM CCK-8 (10 expt, 107 cells) or 277 _+ 19 n M f o r  l ~tM 
JMV-180 (12 expt, 142 cells). The periodicity of Ca 2+ oscillations 
stimulated by CCK and JMV-180 was similar to that previously 
reported; oscillations stimulated by JMV-180 were somewhat 
more rapid than those evoked by low concentrations of CCK-8 
(16). The pattern of Ca 2+ signal evoked by CCK-8 has been 
shown to be influenced by the concentration of agonist applied; 
at higher concentrations of CCK-8 an oscillating Ca 2÷ signal is 
superseded by a rapid peak followed by a plateau that is main- 
rained throughout the period ofagonist exposure [Fig. I(A-C)]. 
In contrast, JMV-180 has been shown to exclusively initiate an 
oscillatory Ca 2÷ signal [Fig. I(D-F)]. After initiation of a Ca 2+ 
signal with CCK-8 (10 pM-1 nM), concurrent superfusion of 
0.1 #M L-364,718, a benzodiazapine derivative, which is a spe- 
cific antagonist of the CCKA receptor (5), resulted in a rapid, 
marked attenuation of the Ca 2+ signal [Fig. I(A-C)] (10 pM: 3 
expt, 56 cells: 100 pM: 3 expt, 23 cells; 1 nM: 2 expt, 12 ceils). 
Cells stimulated with 1 uM CCK-4 also increased [CaZ+]i in an 
oscillatory manner to a peak of 248 + 30 nM (6 expt, 76 cells). 
Oscillations stimulated by CCK-4 were also inhibited by 0.1 ttM 
L-364,718 (Fig. 2) (3 expt, 26 cells), indicating that the terminal 
four amino acid fragment of CCK-8 induces similar Ca 2+ sig- 
naling to CCK-8, although with decreased affinity. In contrast, 
oscillations induced by JMV-180 over the concentration range 
of 25 nM-I  /zM were essentially unaffected by concurrent su- 
perfusion of L-364,718 at similar concentrations [Fig. I(D-F)] 
(25 nM: 3 expt,15 cells; 100 riM: 3 expt, 13 cells; 1/~M: 3 expt, 
34 cells). The effect of L-364,718 was not assessed below 25 nM 
JMV- 180 because these concentrations rarely induced prolonged, 
regular Ca 2+ oscillations. 
Lorglumide Inhibits Ca 2+ Oscillations Induced by CCK But 
Not JMV-180 
To determine that the differential effect of L-364,718 to in- 
hibit CCK-8- but not JMV-180-indueed oscillations was not 
unique to one chemical class of antagonist, the effects of lor- 
glumide (5,14,17), a potent glutaramic acid derivative antagonist, 
were studied. In cells stimulated with low concentrations of CCK- 
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FIG. I. L-364,718 inhibits CCK- but not JMV-180-induced Ca 2+ signaling• (A-C) Superfusion of CCK-8 induces an increase in [Ca2+]i. Concurrent 
superfusion of L-364,718 rapidly attenuates the rise in [Ca2+]i. (D-F) In contrast, oscillations stimulated by JMV-180 are unaffected by L-364,718, 
even at greater concentrations. 
8, Ca 2+ oscillations were rapidly inhibited by concurrent super- 
fusion with 10/~M lorglumide [Fig. 3(A)] (4 expt, 32 cells). Os- 
cillations stimulated by superfusion of CCK-4 were also inhibited 
by lorglumide (2 expt, 40 cells). In contrast, oscillations initiated 
by superfusion of JMV- 180 (100 nM or 1/zM) were largely un- 
affected by administration of  10/zM lorglumide [Fig. 3(B)] (100 
nM: 3 expt, 34 cells; 1 #M: 4 expt, 33 cells)• Furthermore, this 
differential antagonism could be seen in individual cells stim- 
ulated with both agonists. In cells first stimulated with 20 pM 
CCK-8, [Ca2+]i oscillations could be inhibited by lorglumide; 
however, in the continued presence of  the antagonist, [Ca2+]i 
oscillations could still be initiated by JMV-180 (1 /zM) [Fig. 
3(C)1. 
JMV-179 Inhibits Ca 2+ Oscillations Induced by Both CCK 
and JMV-180 
A third recently described CCKA antagonist is a D-Trp-sub- 
stituted analogue of JMV-180, termed JMV-179, which has been 
shown to exhibit characteristics of a pure antagonist (22). Because 
this molecule has close structural similarities to both CCK and 
JMV- 180, its ability to inhibit Ca 2+ signaling by these molecules 
was tested. In cells stimulated by CCK, in which oscillations 
had been initiated, concurrent supeffusion of 1 g M  JMV-179 
resulted in the complete inhibition of the signal [Fig. 4(A)] (3 
expt, 19 cells). In a similar manner, JMV- 179 at concentrations 
in 10-fold excess markedly attenuated the oscillating Ca 2+ signal 
stimulated by 100 n M o r  1/~MJMV-180 [Fig. 4(B,C)] (100 riM: 
5 expt, 84 cells; 1 ~M: 5 expt, 75 cells). The attenuation of tbe  
signal was somewhat more rapid with lower concentrations of 
JMV- 180 [compare Fig. 4(B) and 4(C)] and when the JMV- 179 
was added in 100-fold excess (data not shown). This inhibition 
of JMV-180-induced Ca 2+ signaling by JMV-179 was also evi- 
dent in cells preexposed to L-364,718 (3 expt, 12 cells) [Fig. 
4(C)], possibly indicating that inhibition of Ca 2÷ signaling by 
JMV-179 and L-364,718 is not mediated by binding to an iden- 
tical site on the receptor• 
Effects of CCKa Antagonists on CCK- and JMV-180-Induced 
Amylase Secretion 
The primary physiological consequence of [Ca2+]i oscillations 
induced by CCK-8 and JMV-180 is the secretion of digestive 
enzymes from the pancreatic acinar cell• The above data would 
predict that enzyme secretion in response to CCK-8 would be 
100 
1 f~M CCK-,4 
FIG. 2. L-364,718 inhibts CCK-4-induced Ca 2+ signaling. Superfusion 
of CCK-4 induces an oscillatory increase in [Ca~+]i, which is rapidly 
attenuated by concurrent superfusion with L,364,718. 
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FIG. 3. Lorglumide inhibits CCK- but not JMV-180-induced Ca 2÷ sig- 
naling. (A) Ca 2÷ oscillations induced by CCK are rapidly inhibited by 
lorglumide back to basal values. (B) In contrast, Ca 2÷ oscillations stim- 
ulated by JMV-180 are largely unaffected. (C) In a similar manner to 
(A), Ca 2+ oscillations stimulated by CCK are inhibited by lorglumide. 
After CCK is removed in the continued presence of lorglumide, Ca 2÷ 
oscillations can still be initiated by JMV-180. 
inhibited by all receptor antagonists. In contrast, secretion in- 
duced by JMV-180 should only be affected by JMV-179, but 
not by L,364,718 and lorglumide. That this is indeed the case, 
as shown in Table 2. Amylase secretion in response to an op- 
timum concentration of CCK-8 (100 pM) increased from basal 
values of 4.2 +_ 0.8% of total to 22.2 + 1.9% (n = 4). The increase 
above basal was markedly inhibited by L-364,718 (91% reduc- 
tion), lorglumide (74% reduction), and JMV-179 (>99% reduc- 
tion). In contrast, secretion induced by 1 ~ JMV- 180 was not 
significantly attenuated by L-364,718 (14% reduction) or lor- 
glumide (no inhibition). However, treatment with 10/a3,/JMV- 
179 reduced the responses induced by JMV-180 by 96%. 
D I S C U S S I O N  
Studies of structure-activity relationships for CCK and its 
analogues have defined regions of the peptide that are essential 
for binding and the consequent stimulation of intracellular sig- 
naling and biological responses. CCK-8, containing an unsul- 
phated tyrosine, initiates the full spectrum of biological events, 
although it is some 1000 times less potent when compared to 
CCK-8 containing Tyr(SO3H), and thus a sulphated Tyr is re- 
quired for full potency of the peptide (11,18). Carboxy-terminus 
fragments of CCK-8 as short as CCK-4 (see Table 1) will stim- 
ulate a full range of physiological events in rat and mouse acini, 
including binding to at least two affinity states of the receptor 
and the stimulation of biphasic amylase secretion (21). These 
dam suggest that the four terminal amino acids confer important 
information for the correct interaction of the CCK to its receptor 
even though the potency of CCK-4 is 30,000-100,000-fold 
weaker compared to sulphated CCK-8 (21). The above studies 
indicate that interaction of the CCK peptide with multiple res- 
idues on the CCKA receptor may be important for fully potent 
and efficacious transduction of the signal. At a minimum, a 
residue in the receptor appears to interact with the sulphated 
Tyr moiety in the amino-terminal of the peptide to confer po- 
tency, whereas the carboxy-terminal four amino acids convey 
information regarding the range of biological responses stimu- 
A 4oo 2O p M  C C K  
2SO ~ ~ i I ~ I pM JMV-17e 
100 ,,~ - be ~,/ u' ~L,:-=..:~_~ . - ;=~..%~.=%~,;,--y'-.-:~-, 
200 eeo 
B soo 100 nM ~ 1 1 1 0  
1 ~ JMV-I~,e 
2oo mm 
-- C 1 ~ JM~. lao  
3E~ r" )[ 10 # JI~IV-171 
l o o  ~ 
2 o o  ~ 
1 ~ JMV-180 
D o.1 pM 1. , , l~71= 
300 -- 10 B,M JM~179 
FIG. 4. JMV-179 inhibits oscillations stimulated by both CCK-8 and 
JMV- 180. (A) Ca 2÷ e~,,cillations stimulated by ~ are inhibited by con- 
current incubation with JMV. 179. (B,C) Ca 2÷ c~eillations stimLtlated by 
JMV-180 are also markedly attenuated by concurrent superfusion with 
JMV- 179 at concentrations in tenfold excess. (D) Oscillations stimulated 
by JMV-180 are also inhibited by JMV-179 in the continued presence 
of L-364,718. 
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TABLE 2 
AMYLASE SECRETION STIMULATED BY CCK AND JMV-180 IS 
DIFFERENTIALLY INHIBITED BY ANTAGONISTS OF 
CCKA RECEPTORS 
L-364,718 Lorglumide JMV- 179 
No Addition (0.1 gdld) (10 gg) (10 ;zM) 
Basal 4.2 _ 0.8 4.2 _+ 0.3 5.1 + 0.6 5.5 _+ 0.5 
CCK-8 (100 pM) 22.2 + 1.9 5.7 ___ 0.3 9.5 ± 0.6 5.6 _+ 1.9 
JMV-180(I #M) 22.5 ± 2.5 20.1 + 0.6 22.4 ± 1.5 6.1 + 1.4 
Amylase secretion stimulated by optimum concentrations of CCK-8 
and JMV-180 over 30 min was compared in the presence and absence 
of the indicated antagonists: L-364,718, lorglumide, and JMV- 179. Data 
are the mean _+ SEM of three to four experiments and represent the 
percent of total amylase released compared with the total measured in 
the pellets. In individual experiments amylase release for each condition 
was determined in triplicate. 
cholamine receptors has indicated that ligand binding is deter- 
mined by interaction with at least three residues within the bind- 
ing pocket formed between transmembrane domains; serine 
residues in the fifth transmembrane domain interact with hy- 
droxyl moieties, whereas a phenylalanine residue in the sixth 
transmembrane domain is important for interaction with the 
aromatic ring structure of catecholamines (25). An aspartate 
residue in the third transmembrane domain is the third require- 
ment essential for fully efficacious binding of biogenic amines 
to their receptors. The aspartate residue appears important in 
recognition of the amine portion of the molecule because this 
residue is highly conserved in other receptors that bind amines, 
such as the muscarinic acetylcholine receptor (4,24). 
This model (Fig. 5) predicts that classical antagonists of the 
CCKA receptor are not effective in inhibiting the responses stim- 
ulated by JMV-180 because interaction of antagonist with re- 
ceptor does not interfere with binding to the discrete sites needed 
for JMV-180 activity. Although not necessary for the model, in 
lated. This later receptor site is sensitive to the amidated carboxyl- 
terminal of the peptide, as CCK derivatives with a free carboxyl 
group are biologically inactive (18). 
Modification of  CCK-8 to form JMV-180 (Table 1) has also 
yielded important information because this molecule only in- 
teracts with one affinity state of the receptor and stimulates a 
subset of CCK-8's action (6,7,15,16,19,23,26,31). The important 
modification to the JMV- 180 molecule appears to be to the car- 
boxy-terminus of the molecule where aspartate is linked by an 
ester bond to phenylamine instead of the peptide bond linkage 
to the terminal-amidated phenyalanine in CCK-8. Other mod- 
ifications to the JMV-180 molecule, including substitution of 
nodeucine for methionine residues and the presence of an amino- 
terminal t-butyloxycarbonyl group, only confer increased sta- 
bility to the molecule because these substitutions in CCK-7 or 
CCK-9 do not affect biological activity (7). 
We have shown that Ca 2+ signaling and amylase secretion 
stimulated by CCK and JMV- 180 are differentially inhibited by 
antagonists of the CCKA receptor; that is, antagonists from dis- 
tinct chemical classes inhibit responses stimulated by CCK but 
are largely ineffective at attenuating responses initiated by JMV- 
180 over a large concentration range. That this affect appears 
to be an integral property of the receptor and not a function of 
JMV- 180 binding irreversibly to the receptor is indicated by the 
inability of nonpeptide antagonist to inhibit JMV- 180-stimulated 
Ca 2+ signaling when the antagonist has been incubated prior to 
superfusion of JMV-180 [Fig. 3(C)]. 
One manner in which this paradoxical data can be reconciled 
is by the model shown in Fig. 5, representing the high-affinity 
state of the CCKA receptor, in which CCK-8/CCK-4 and JMV- 
180 bind to discrete residues on the CCKA receptor. Both CCK- 
8 and CCK-4 are envisioned to interact with multiple sites, 
whereas JMV- 180, because of modifications to the C-terminus, 
is only capable of binding to a subset of the sites needed for full 
biological activity [Fig. 5(A-C)]. Thus, the binding ofJMV- 180 
could result in a unique conformational change leading to the 
observed distinct biological events, such as guanine nucleotide- 
insensitive binding and the apparent stimulation of 1,4,5-IP3 
independent Ca 2+ signaling (6,19,26,3 I). Little information is 
available regarding specific amino acid residues or domains of 
the CCKA receptor that are important for interaction with the 
peptide. However, evidence from the study ofbacteriorhodopsin, 
together with the cholinergic and adrenergic receptor, suggests 
that multiple regions of the receptor may be important for correct 






FIG. 5. Model of CCK and JMV-180 binding to the CCK^ receptor. 
Cartoon represents a model in which CCK and JMV-180 bind to different 
sites on the CCKA receptor. (A) CCK-8 binding to the receptor. (B) 
CCK-4 binding to the receptor. (C) JMV-180 binding to the receptor. 
(D) Nonpeptide antagonist binding (L-364,718, lorglumide) inhibits the 
binding of CCK by altering the conformation of the receptor. (E) Altered 
conformation of the receptor is not sufficient to inhibit JMV-180 binding. 
(F) JMV- 179 binding, by occupying the sites required for JMV- 180 action, 
inhibits both JMV- 180 and CCK. 
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the cartoon shown in Fig. 5 the b ind ing  of antagonis t  is de- 
picted as occurring at a dist inct  site somewhat  dis tant  to the 
agonist b ind ing  pocket. Evidence for this is not  available re- 
lating to the CCKA receptor, bu t  a recent study has indicated 
that a region impor tan t  for nonpept ide  antagonis t  b ind ing  is 
located in the sixth t ransmembrane  loop of the CCKB receptor, 
because subst i tu t ion of a single a mi n o  acid in posit ion 319 
dramatically alters nonpeptide antagonist  b inding  properties, 
without  affecting the b ind ing  of agonists. A similar  s i tuat ion 
has been reported for the tachykin in  receptor; chimeric sub- 
st i tut ion of  a 17 am i n o  acid region between NK~ and  NK2 
receptors reverses antagonis t  specificity without  altering ag- 
onist binding. The authors of these studies therefore concluded 
that agonist and  antagonis t  de te rminan t  residues reside in 
differing regions of the receptor (1,8). 
Data in Fig. 4 show that JMV- 179 will antagonize Ca 2÷ sig- 
naling and amylase secretion not only elicited by CCK-8, but 
also by JMV-180 [Fig. 4(A-C)]. Although the mechanism for 
JMV- 179-mediated inhibit ion is unknown at this time, it seems 
likely that because this molecule is very similar in structure to 
JMV-180 (Table 1), having only one substitution (D-Trp for L- 
Trp), that it interacts with the same site(s) in the receptor as 
JMV-180. Thus, inhibit ion of JMV-180 binding could occur as 
a function of competition for this site. That the sites sufficient 
for JMV-179-mediated inhibit ion may differ from those nor- 
mally occupied by nonpeptide antagonists such as L-364,718 is 
indicated by the ability of JMV-179 to inhibit responses to JMV- 
180 in the presence of the nonpeptide antagonist. Inhibition of 
CCK-8 responses would then occur as occupation of the site 
normally occupied by JMV-180 would interfere with binding 
of CCK-8 [Fig. 5(F)]. 
In the present study, we reported differences in the ability of 
antagonists of the CCKA receptor to inhibit  responses elicited 
by CCK and its partial agonist JMV- 180. We proposed a model 
based on the binding of JMV-180 and CCK to differing yet 
overlapping sites or residues in the CCKA receptor to explain 
not  only the differing susceptibility to antagonists but  maybe to 
explain how two agonists binding to one receptor can elicit dif- 
fering physiological responses. 
ACKNOWLEDGEMENTS 
This work was supported by NIH Grant DK41225, the Michigan 
Gastrointestinal Peptide Center (DK34933), and by the Michigan Dia- 
betes Research and Training Center (DK20572). The authors wish to 
thank E. Steunkel and C. Logsdon for helpful discussion during the 
period of this study. 
R E F E R E N C E S  
1. Beinborn, M.; Lee, Y-M.; McBride, E. W.; Quinn, S. M.; Kopin, 
A. S. A single amino acid of the cholecystokinin-B/gastrin receptor 
determines specificity for non-peptide antagonists. Nature 362:348- 
350; 1993. 
2. Blevins, G. T.; Williams, J. A. ATP induces two cholecystokinin 
binding affinity states in permeabilized rat pancreatic acini. Am. J. 
Physiol. 263:G44-G51 ; 1992. 
3. Brooker, G.; Seki, T.; Croll, D.; Wahlestedt. C. Calcium wave evoked 
by activation of endogenous or exogenously expressed receptors in 
Xenopus oocytes. Proc. Natl. Acad. Sci. USA 87:2813-2817; 1990. 
4. Fraser, C. M.; Wang, C-D.; Robinson, D. A.; Gocayne, J. D.; Venter, 
J. C. Site directed mutagenesis of m 1 muscarinic acetylcholine re- 
ceptors: Conserved aspartic acids play important roles in receptor 
function. Mol. Pharmacol. 36:840-847; 1989. 
5. Freidinger, R. M. Cholecystokinin and gastrin antagonists. Med. 
Res. Rev. 9:271-290; 1989. 
6. Galsano, H. Y.; Klueppelberg, U. G.; Pinon, D. I.; Pfenning, M. A.; 
Powers, S. P.; Miller, L. J. Novel tool for the study ofcholecystokinin- 
stimulated enzyme secretion. J. Clin. Invest. 83:321-325; 1989. 
7. Galas, M. C.; Lignon, M. F.; Rodriguez, M.; et al. Structure activity 
relationships studies on cholecystokirdn: Analogues with partial ag- 
onist activity. Am. J. Physiol. 254:G176-G182; 1988. 
8. Gether, U.; Yokato, Y.; Emonds-Alt, X.; et al. Two nonpeptide 
tachykinin antagonists act through epitopes on corresponding seg- 
ments of the NKt and NK2 receptor. Prec. Nat. Acad. Sci. USA 90: 
6194-6198; 1993. 
9. Grynkiewicz, G.; Poenie, M.; Tsien, R. Y. A new generation of Ca 2+ 
indicators with greatly improved fluorescent properties. J. Biol. 
Chem. 260:3440-3450; 1985. 
10. Jensen, R. T.; Letup, G. F.; Gardner, J. D. Interaction ofcholecys- 
tokinin with specific membrane receptors on pancreatic acinar cells. 
Prec. Natl. Acad. Sci. USA 77:2079-2083; 1980. 
11. Johnson, L. R.; Stening, G. F.; Grossman, M. I. Effects ofsulphation 
on the gastrointestinal actions of caerulein. Gastroenterology 58: 
208-216; 1970. 
12. Jung, D. H. Preparation and application of procion yellow starch 
for amylase assay. Ciin. Chem. Acta 100:7-11; 1980. 
13. Korc, M.; Williams, J. A.; Goldfine, I. D. Stimulation of the glucose 
transport system in isolated mouse pancreatic acini by cholecysto- 
kinin and analogues. J. Biol. Chem. 252:7624--7629; 1979. 
14. Makovec, F.; Bard, M.; Chiste, L. R.; Revel, L.; Rovati, L. C.; Rovati, 
L. A. Differentiation of central and peripheral cholecystokinin re- 
ceptors by new glutaramic acid derivatives with cholecystokinin- 
antagonist activity. Arzneimittelforschung 36(1 ):98-102; 1986. 
15. Matozaki, T.; Martinez, J.; Williams, J. A. A new CCK analogue 
differentiates two functionally distinct CCK receptors in rat and 
mouse acini. Am. J. Physiol. 257:G594-G600; 1989. 
16. Matozaki, T.; Goke, B.; Tsunoda, Y.; Rodriguez, M.; Martinez, J.; 
Williams. J. A. Two functionally distinct cholecystokinin receptors 
show different modes of actions on Ca 2+ mobilization and phos- 
pholipid hydrolysis in isolated rat pancreatic acini. J. Biol. Chem. 
265:6247-6254; 1990. 
17. Niederau, C.; Niederau, M.; Williams, J. A.; Grendell, J. H. New 
proglumide-analogue CCK receptor antagonists: Very potent and 
selective for peripheral tissues. Am. J. Physiol. 251:G856-G860; 
1986. 
18. Rehfield. J. F. Four basic characteristics of the gastrin-cholecystokinin 
system. Am. J. Physiol. 240:G255-G266; 1981. 
19. Saluja, A. K.; Dawra, R.; Lerch, M.; Steer, M. L. CCK-JMV-180, 
an analogue of cholecystokinin, releases calcium from an inositol 
trisphosphate independent pool in rat pancreatic acini. J. Biol. Chem. 
267:11202-11208; 1992. 
20. Sankaran, H.; Goldfine, I. D.; Deveney, C. W.; Wong, E. Y.; 
Williams, J. A. Binding of cholecystokinin to high affinity recep- 
tors on isolated rat pancreatic acini. J. Biol. Chem. 255:1849- 
1853; 1980. 
21. Sankaran, H.; Bailey, A. C.; Williams, J. A. CCK-4 contains full 
hormonal information of cholecystokinin in isolated pancreatic 
acini. Biochem. Biophys. Res. Commun. 103(4):1356-1362; 
1981. 
22. Silvente-Poirot, S.; Hadjivanova, C.; Escrieut, C.; et al. Study of the 
states and populations of the rat pancreatic cholecystokinin receptor 
using the full peptide antagonist JMV-179. Eur. J. Biochem. 212: 
529-538; 1993. 
23. Stark, H. A.; Sharp, C. M.; Sutliff, V. E.; Martinez, J.; Jensen, 
R. T.; Gardner, J. D. CCK-JMV-180: A peptide that distinguishes 
high-affinity from low-affinity cholecystokinin receptors. Biochem. 
Biophys. Acta 1010:145-150; 1989. 
24. Strader, C. D.; Sigal, I. S.; Register, R. B.; Candelore, M. R.; Rands, 
E.; Dixon, R. A. Identification of residues required for ligand binding 
to the bcta-adrenergic receptor. Prec. Natl. Aead. Sci. USA 84:4384- 
4388; 1987. 
25. Strader, C. D.; Sigal, I. S.; Dixon, R. A. Structural basis of beta 
adrenergic receptor function. FASEB J. 3:1825-1832; 1989. 
CCK A N D  SIGNAL T R A N S D U C T I O N  1051 
26. Tsunoda, Y.; Owang, C. Differential involvement ofphospholipase 
A2/phosphoinositol pathways during cholecystokinin receptor ac- 
tivated Ca 2+ oscillations in pancreatic acini. Biochem. Biophys. Res. 
Commun. 194:1194-1202; 1993. 
27. Weiss, J. Mutational analysis of muscarinic acetylcholine receptors: 
Structural basis of ligand/receptor/gprotein interactions. Life Sci. 
53:1447-1463; 1993. 
28. Williams, J. A.; Korc, M.; Dormer, R. L. Action of secretagogues 
on a new preparation of functionally intact, isolated pancreatic acini. 
Am. J. Physiol. 235:E517-E524; 1978. 
29. Williams, J. A.; Blevins, G. T., Jr. Cholecystokinin and regulation 
of pancreatic acinar cell function. Physiol. Rev. 73(4):701-723; 1993. 
30. Williams, J. A.; Yule, D. I. Stimulus-secretion coupling in pancreatic 
acinar cells. In: Go, V. W., eel. The pancreas, biology pathobiology 
and disease. New York: Raven Press; 1993:167-189. 
31. Yule, D. I.; Williams, J. A. U73122 inhibits Ca 2+ oscillations in 
response to cholecystokinin and carbachol but not JMV-180 in rat 
pancreatic acini. J. Biol. Chem. 267:13830-13835; 1992. 
32. Yule, D. I.; Tseng, M-J.; Williams, J. A.; Logsdon, C. D. A cloned 
CCK-A receptor transduces multiple signals in response to full and 
partial agonists. Am. J. Physiol. 265:G999-G1004; 1993. 
33. Yule, D. I.; Wu, D.; Essington, T. E.; Shayman, J. A.; Williams, 
J. A. Sphingosine metabolism induces Ca 2+ oscillations in rat pan- 
creatic acinar cells. J. Biol. Chem. 268:12353-12358; 1993. 
